| Publications by Biophoenix' Principals |
| European Market for DNA Probe Diagnostic Products and Services | |
|---|---|
 | |
| Publisher: | Frost & Sullivan Inc |
| Year of publication: | 1990 |
| Type of publication: | Market report |
| Publisher's reference (if any): | E1391 |
| Author(s): | Sreten Bogdanovic |
| Approximate page count: | 320 |
| Price when published: | $3,400 |
Remarks:
| |
EUROPEAN MARKET FOR DNA PROBE DIAGNOSTIC
PRODUCTS AND SERVICES
FROST & SULLIVAN INC., E1391
JULY 1990
TABLE OF CONTENTS
Page
TABLE OF CONTENTS TOC.1
LIST OF TABLES TOC.14
EXECUTIVE SUMMARY ES.1
CHAPTER 1 INTRODUCTION, SCOPE, METHODOLOGY, AND DEFINITIONS
1.1 Introduction 1.1
1.1.1 What is DNA Diagnostics? 1.1
1.1.2 How Do DNA Tests Work? 1.4
1.1.3 The Development of DNA Tests 1.7
1.1.4 History of the Modern Biotechnology
Industry 1.11
1.1.5 The Biotechnology Industry Today 1.13
1.1.6 The Biotechnology Industry and Society 1.15
1.2 Objectives and Scope of this Report 1.16
1.2.1 Major Objectives 1.16
1.2.2 Scope of the Report 1.17
1.2.3 Report Summary 1.20
1.3 Research Methodology 1.22
1.4 Abbreviations and Definitions 1.23
1.5 Exchange Rates Used in Compiling this Report 1.26
CHAPTER 2 CORE TECHNOLOGIES AND APPLICATIONS
2.1 Introduction 2.1
2.2 Proteins 2.1
2.2.1 Functions of Proteins 2.1
2.2.2 Structure of Proteins 2.2
2.3 Nucleic Acids: DNA 2.3
2.3.1 Introduction 2.3
2.3.2 DNA and Genes 2.3
2.3.3 The Structure of DNA 2.4
2.3.4 DNA and Chromosomes 2.6
2.3.5 Chromosomes and Genes 2.6
2.3.5.1 Alleles 2.6
2.3.5.2 Heterozygosity and Polymorphism 2.7
2.3.5.3 Genetic Linkage 2.8
2.3.5.4 Recombination 2.8
2.3.5.5 Genetic Mapping 2.9
2.3.6 Chromosomes and Cytogenetics 2.11
2.3.6.1 Nomenclature 2.11
2.3.6.2 Chromosomal Aberrations 2.12
2.3.6.3 Karotypes 2.13
2.3.6.4 DNA Methods in Cytogenetics 2.14
2.3.7 Replication of DNA 2.15
2.3.7.1 Introduction 2.15
2.3.7.2 The Direction of DNA Replication 2.15
2.3.7.3 DNA Polymerase and the Polymerase
Chain Reaction (PCR) 2.16
2.3.7.3.1 Introduction 2.16
2.3.7.3.2 The Need for PCR 2.16
2.3.7.3.3 What PCR Can Do 2.16
2.3.7.3.4 Performing the PCR 2.17
2.3.7.3.5 Uses and Drawbacks of PCR 2.19
2.3.7.3.6 Current Position of PCR: Cetus
vs Du Pont 2.20
2.3.8 The Genetic Code 2.21
2.3.8.1 Codons 2.21
2.3.8.2 Universality of the Genetic Code 2.22
2.3.9 The Structure of Genes 2.23
2.3.9.1 Coding and Regulatory Sequences 2.23
2.3.9.2 Non-Coding DNA 2.24
2.3.9.3 The Relative Sizes of Genomes 2.25
2.3.9.4 Satellite and Minisatellite DNA 2.25
2.3.9.5 DNA Profiling 2.26
2.4 Nucleic Acids: RNA 2.29
2.4.1 Introduction 2.29
2.4.2 Origin of RNA 2.29
2.4.3 Types of RNA 2.30
2.4.4 RNA Viruses 2.32
2.4.5 Transcription and RNA Processing 2.33
2.4.5.1 Transcription and the Control of
Gene Expression 2.33
2.4.5.2 RNA Probes 2.33
2.4.5.3 Processing of Newly-Synthesised RNA 2.34
2.4.5.3.1 Cutting and Trimming 2.34
2.4.5.3.2 Splicing 2.35
2.4.5.3.3 Capping and Tailing 2.36
2.4.5.4 RNA Processing and Gene Expression 2.36
2.4.5.5 Protein Synthesis 2.36
2.5 Development of Diagnostic DNA Probes 2.37
2.5.1 Overview 2.37
2.5.2 Development of Probes of Clonal Origin 2.38
2.5.3 An Example: DNA Probes in Haemoglobin
Disorders 2.38
2.5.4 DNA Probes for Genetic Disorders of
Unknown Aetiology 2.40
2.5.5 DNA Probes for Infectious Diseases 2.40
2.6 DNA Probes in Medical Genetics and Related
Areas 2.41
2.6.1 Introduction 2.41
2.6.2 Types of Mutation seen in Genetic Disease 2.42
2.6.3 DNA Testing in Genetic Disease 2.44
2.6.3.1 The Importance of Genetic Linkage 2.44
2.6.3.2 The Family Study 2.45
2.6.3.3 The Role of Restriction Enzymes 2.47
2.6.3.4 Gel Electrophoresis, Blotting, and
Probing 2.47
2.6.3.5 Restriction Fragment Length
Polymorphisms (RFLPs) 2.48
2.6.4 Practical DNA Testing in Genetic Disease 2.49
2.6.4.1 Assay Procedures 2.49
2.6.4.2 Sources of Sample Material 2.51
2.6.4.3 Pre-Implantation Diagnosis 2.52
2.7.4 Detecting Genetic Disease in utero 2.53
2.7.4.1 Introduction 2.53
2.7.4.2 Analysis of Amniotic Fluid 2.54
2.7.4.3 Enzyme Assays in Cultured Amniocytes 2.54
2.7.4.4 Chorionic Villus Sampling (CVS) 2.55
2.7.4.5 Analysis of Foetal Blood and
other Tissues 2.56
2.7.4.6 Ultrasound 2.56
2.7.8 Other Genetics-related Applications of
DNA Diagnostics 2.57
2.7.8.1 Pre-employment Screening 2.57
2.7.8.2 Plant and Animal Diagnostics 2.58
2.7.8.3 Security-related Applications 2.58
2.8 DNA Diagnostics and Cancer 2.59
2.8.1 Introduction 2.59
2.8.1.1 Somatic and Germ-Line DNA 2.59
2.8.1.2 Tumour Progression 2.59
2.8.1.3 Inherited Cancers 2.61
2.8.2 The Genetics of Cancer 2.62
2.8.2.1 Introduction 2.62
2.8.2.2 Retinoblastoma 2.63
2.8.2.3 Other Deletion-associated Tumours 2.64
2.8.2.4 Anti-oncogenes 2.64
2.8.3 Oncogenes 2.66
2.8.3.1 Viruses and Cancer 2.66
2.8.3.2 Viruses and Oncogenes 2.66
2.8.3.3 Other Tumorigenic Viral Nucleic
Acids 2.67
2.8.3.4 Functions of Oncogenes and their
Products 2.67
2.8.4 DNA Diagnosis of Cancer 2.71
2.9 Sample Preparation 2.72
2.10 Assay Formats 2.74
2.10.1 Introduction 2.74
2.10.2 Heterogeneous Assays 2.75
2.10.2.1 Dot and Slot Blotting 2.75
2.10.2.2 Southern Blotting 2.75
2.10.2.3 In Situ Hybridisation 2.76
2.10.2.4 Affinity Capture Techniques 2.77
2.10.3 Homogeneous Assays 2.78
2.10.4 Assays Adaptable to Solid or Liquid
Phases 2.79
2.10.4.1 Strand Displacement 2.79
2.10.4.2 Sandwich Hybridisation 2.79
2.10.5 Assays for New Mutations 2.81
2.10.5.1 Introduction 2.81
2.10.5.2 Heteroduplex Mapping 2.81
2.10.5.3 Denaturing Gradient Gel
Electrophoresis 2.82
2.10.6 Reversed Hybridisation 2.82
2.11 Nucleic Acid Labelling Systems 2.83
2.11.1 Incorporation of Labels into DNA and RNA 2.83
2.11.2 Radioisotopes 2.84
2.11.2.1 Introduction 2.84
2.11.2.2 Phosphorus-32 2.84
2.11.2.3 Sulphur-35 2.85
2.11.2.4 Tritium 2.85
2.11.2.5 Iodine-125 and Iodine-131 2.85
2.11.2.6 Carbon-14 2.86
2.11.3 Nonisotopic Labels 2.86
2.11.3.1 Introduction 2.86
2.11.3.2 Biotin Tagging 2.87
2.11.3.3 Labels for use with Biotin 2.88
2.11.3.4 Incorporation of Biotin Tags into
DNA 2.89
2.11.3.5 Other DNA Probe Tags 2.89
2.11.3.6 Direct Labelling of DNA 2.90
2.11.4 DNA Sensors 2.91
CHAPTER 3 DNA DIAGNOSTIC PRODUCTS AND SERVICES
3.1 Introduction 3.1
3.2 DNA Preparation 3.1
3.2.1 Solvent or Organic Extraction 3.1
3.2.2 Kit-based DNA Extraction Methods 3.2
3.2.3 Extraction of mRNA 3.3
3.3 DNA Amplification 3.3
3.3.1 Introduction 3.3
3.3.2 Polymerase Chain Reaction (PCR) 3.4
3.3.2.1 PCR Products 3.4
3.3.2.2 PCR Aftermarket Products 3.5
3.3.2.2.1 Intelligent Incubators 3.5
3.3.2.2.2 Primers and Probes 3.6
3.3.3 Ligase Chain Reaction 3.7
3.3.4 Q-beta Replicase Amplification System 3.8
3.3.4.1 Basic Configuration 3.8
3.3.4.2 Problems and Modifications 3.9
3.4 Genetics-Related Products and Services 3.10
3.4.1 Introduction 3.10
3.4.2 Monogenic Disorders 3.11
3.4.2.1 Alpha-1-antitrypsin Deficiency 3.11
3.4.2.2 Congenital Adrenal Hyperplasia 3.12
3.4.2.3 Cystic Fibrosis 3.12
3.4.2.3.1 Basic Genetics of CF 3.12
3.5.2.3.2 Direct Testing for CF 3.13
3.4.2.4 Duchenne Muscular Dystrophy 3.15
3.4.2.5 The Haemophilias 3.17
3.4.2.6 Huntingdon's Disease 3.17
3.4.2.7 Neurofibromatosis 3.18
3.4.2.8 Myotonic Dystrophy 3.19
3.4.2.9 Phenylketonuria 3.19
3.4.2.10 Polycystic Kidney Disease 3.20
3.4.2.11 Proximal Spinal Muscular Atrophy 3.20
3.4.2.12 The Haemoglobinopathies 3.21
3.4.2.13 The Fragile-X Syndrome 3.22
3.4.3 Chromosomal Disorders 3.22
3.4.4 Market Nature 3.25
3.4.4.1 DNA Testing Sites 3.25
3.4.4.2 Economics of DNA Testing and Screening 3.26
3.4.4.3 Expected Workload in a DNA Reference
Laboratory 3.27
3.4.5 DNA Fingerprinting 3.27
3.4.5.1 Introduction 3.27
3.4.5.2 Applications 3.28
3.4.5.3 The First Two Years: Commercial
Development 3.29
3.4.5.4 The First Two Years: In the Courts 3.31
3.4.5.5 The First Two Years: European
Regulation 3.33
3.5 DNA Probes and Cancer Diagnostics 3.34
3.5.1 Introduction 3.34
3.5.2 bcr analysis 3.38
3.5.3 Other translocation malignancies 3.39
3.5.4 B/T cell DNA analysis 3.40
3.5.5 Cervical Cancer 3.42
3.5.6 Market Nature 3.43
3.6 Infectious Disease Diagnostics 3.44
3.6.1 Introduction 3.44
3.6.2 Survey of bacterial pathogens 3.47
3.6.2.1 Bacteroides species 3.47
3.6.2.2 Campylobacter 3.47
3.6.2.3 Chlamydia 3.48
3.6.2.4 Gonorrhoea 3.48
3.6.2.5 Legionellosis 3.49
3.6.2.6 Leptospirosis 3.49
3.6.2.7 Mycobacteria 3.50
3.6.2.8 Mycoplasmas 3.50
3.6.2.9 Salmonellae 3.51
3.6.2.10 Other Bacteria 3.51
3.6.3 Survey of viral pathogens 3.52
3.6.3.1 Adenovirus 3.52
3.6.3.2 Cytomegalovirus 3.52
3.6.3.3 Human immunodeficiency virus 3.53
3.6.3.4 Hepatitis 3.54
3.6.3.5 Rotavirus 3.55
3.6.4 Survey of parasitic pathogens 3.56
3.6.4.1 Leishmaniasis 3.56
3.6.4.2 Plasmodium 3.56
3.6.4.3 Tapeworms (Taeniids) 3.57
3.6.5 Immunoassays and DNA probes 3.57
3.6.6 Market nature 3.58
CHAPTER 4 NATIONAL AND END-USER MARKETS
4.1 Introduction 4.1
4.2 Overview of DNA Diagnostics End-Users 4.2
4.3 Belgium 4.4
4.3.1 Introduction 4.4
4.3.2 Health Service Structure 4.5
4.3.3 Clinical Laboratories 4.6
4.3.4 Milk and Dairy Industry 4.8
4.3.5 Food Industry 4.9
4.3.6 Pharmaceutical Industry 4.9
4.3.7 Water Industry 4.9
4.4 France 4.10
4.4.1 Introduction 4.10
4.4.2 Health Service Structure 4.12
4.4.3 Clinical Laboratories 4.12
4.4.4 Milk and Dairy Industry 4.16
4.4.5 Food Industry 4.16
4.4.6 Pharmaceutical Industry 4.16
4.4.7 Water Industry 4.17
4.5 Italy 4.17
4.5.1 Introduction 4.17
4.5.2 Health Service Structure 4.19
4.5.3 Clinical Laboratories 4.21
4.5.4 Milk and Dairy Industry 4.22
4.5.5 Food Industry 4.22
4.5.6 Pharmaceutical Industry 4.23
4.5.7 Water Industry 4.23
4.6 The Netherlands 4.24
4.6.1 Introduction 4.24
4.6.2 Health Service Structure 4.25
4.6.3 Clinical Laboratories 4.26
4.6.4 The Genetics Service 4.29
4.6.5 Milk and Dairy Industry 4.32
4.6.6 Food Industry 4.32
4.6.7 Pharmaceutical Industry 4.33
4.6.8 Water Industry 4.33
4.7 Spain 4.33
4.7.1 Introduction 4.33
4.7.2 Health Service Structure 4.34
4.7.3 Clinical Laboratories 4.35
4.7.4 Non-Medical End-User Industries 4.38
4.8 United Kingdom 4.38
4.8.1 Introduction 4.38
4.8.2 Health Service Structure 4.42
4.8.3 Clinical Laboratories 4.43
4.8.4 Milk and Dairy Industry 4.45
4.8.5 Food Industry 4.45
4.8.6 Water Industry 4.46
4.8.7 Pharmaceutical Industry 4.48
4.9 West Germany 4.49
4.9.1 Introduction 4.49
4.9.2 Health Service Structure 4.51
4.9.3 Clinical Laboratories 4.52
4.9.4 Milk and Dairy Industry 4.55
4.9.5 Food Industry 4.56
4.9.6 Pharmaceutical Industry 4.56
4.9.7 Water Industry 4.56
4.10 Demographic Data 4.57
CHAPTER 5 MARKET ANALYSES AND FORECASTS
5.1 Introduction 5.1
5.2 Genetics-Based Products 5.3
5.2.1 How Big is the Medical Genetics Market? 5.3
5.2.2 Opportunities in Medical Genetics 5.7
5.2.3 Growth of the Medical Genetics Market 5.8
5.2.4 Population Carrier Screening for
Cystic Fibrosis 5.10
5.2.5 DNA Profiling 5.12
5.3 In Vitro Cancer-Related Tests 5.14
5.3.1 HPV Hybridisation Histochemistry 5.14
5.3.2 Evaluation of Tumour DNA 5.15
5.4 DNA Tests for Infectious Disease Agents 5.28
5.4.1 Introduction 5.28
5.4.2 AIDS 5.29
5.4.3 Sexually-Transmitted Diseases 5.30
5.4.4 Gastrointestinal Pathogens 5.31
5.4.5 Mycobacteria 5.32
5.4.6 Hepatitis Viruses 5.32
5.5 DNA Diagnostic Instrumentation 5.33
CHAPTER 6 SUPPLIER PROFILES
6.1 Introduction 6.1
6.2 Abbott Laboratories 6.3
6.3 Amgen 6.5
6.4 Amersham International PLC 6.8
6.5 Applied Biosystems Incorporated 6.11
6.6 Boehringer Mannheim GmbH 6.12
6.7 British Bio-technology Limited 6.15
6.8 California Biotechnology 6.18
6.9 Cetus 6.22
6.10 Chiron 6.25
6.11 Collaborative Research 6.28
6.12 Digene Diagnostics 6.31
6.13 E.I. Du Pont de Nemours & Company 6.33
6.14 Enzo Biochem Incorporated 6.35
6.15 Euro-Diagnostics 6.38
6.16 Gen-Probe Corporation 6.39
6.17 Genzyme/Integrated Genetics 6.42
6.18 ImClone Systems Incorporated 6.46
6.19 Johnson and Johnson 6.48
6.20 Life Technologies Incorporated 6.51
6.21 Molecular Biosystems Incorporated 6.53
6.22 Oncogene Science Incorporated 6.54
6.23 Oncor Incorporated 6.56
6.24 Orgenics Limited 6.57
6.25 Orion Corporation Limited 6.59
6.26 Roche 6.60
CHAPTER 7 TRENDS AND OPPORTUNITIES
7.1 Introduction 7.1
7.2 Product Opportunities in Medical Genetics 7.1
7.2.1 Introduction 7.1
7.2.2 Penetration of the Medical Genetics Market 7.2
7.2.3 Automated Genetic Analysis 7.3
7.2.4 Testing for Polygenic Disorders 7.5
7.2.4.1 Introduction 7.5
7.2.4.2 Alzheimers Disease 7.6
7.2.4.3 Coronary Artery Disease 7.8
7.2.4.4 Diabetes Mellitus 7.8
7.2.4.5 Immunological Diseases 7.9
7.2.4.6 Psychiatric Disorders 7.9
7.2.4.6.1 Schizophrenia 7.9
7.2.4.6.2 Manic-depressive Psychosis 7.11
7.2.4.6.3 Alcoholism 7.12
7.2.5 Conclusions 7.13
7.3 Product Opportunities in Infectious Disease
Testing 7.13
7.4 Product Opportunities in Prion Disease
Diagnostics 7.15
7.4.1 Introduction 7.15
7.4.2 Bovine Spongiform Encephalopathy 7.15
7.4.3 Human Spongiform Encephalopathies 7.16
7.4.4 DNA Diagnosis of Prion Diseases 7.17
7.5 Product Opportunities in Cancer-Related Testing 7.19
7.5.1 Cervical Screening 7.19
7.5.2 Immunoassay Tumour Markers vs DNA Tests 7.19
7.5.3 Oncogene and Related Tests 7.20
7.6 Product/Service Opportunities in DNA Profiling 7.21
7.7 Opportunities Created by the Human Genome
Project 7.22
7.7.1 Introduction 7.22
7.7.2 Organisation 7.23
7.7.3 Strategy 7.24
7.7.4 Benefits from the Genome Project 7.25
7.7.4.1 The Detection of Monogenic Disorders 7.25
7.7.4.2 The Management of Polygenic Disorders 7.25
7.7.4.3 Pharmaceutical Development 7.27
7.7.4.4 Commercial Instrumentation 7.28
7.8 Wider Market Trends 7.29
7.8.1 Decentralised Testing 7.29
7.8.2 Cost Containment and Screening 7.29
7.8.3 Impact of European Public Opinion 7.30
APPENDIX 1 SCHEDULE OF TRADE AND PROFESSIONAL ASSOCIATIONS
A1.1 Trade Asociations A1.1
A1.2 Professional Associations A1.2
APPENDIX 2 JOURNALS AND NEWSLETTERS A2.1
APPENDIX 3 SCHEDULE OF COMPANIES MENTIONED A3.1
LIST OF TABLES
CHAPTER 2 CORE TECHNOLOGIES AND APPLICATIONS
TABLE 2.1
ONCOGENES ACTIVATED BY AMPLIFICATION 2.69
TABLE 2.2
ONCOGENES ACTIVATED BY POINT MUTATION 2.70
TABLE 2.3
ONCOGENES ACTIVATED BY CHROMOSOMAL REARRANGEMENTS 2.71
CHAPTER 3 DNA DIAGNOSTIC PRODUCTS AND SERVICES
TABLE 3.1
TOTAL INCIDENCE OF GENETICALLY-DETERMINED DISEASE 3.10
TABLE 3.2
DISTRIBUTION OF CANCER BY SITE IN WESTERN EUROPE 3.35
TABLE 3.3
THE MOST EXTENSIVELY-STUDIED ONCOGENES 3.37
TABLE 3.4
DNA-BASED PATHOGEN KITS 3.45
TABLE 3.5
DNA DIAGNOSTIC INSTRUMENTATION AND GENERAL
MOLECULAR BIOLOGY REAGENTS 3.59
TABLE 3.6
DNA-BASED GENETICS-RELATED PRODUCTS AND SERVICES 3.60
TABLE 3.7
DNA-BASED IN VITRO CANCER-RELATED PRODUCTS 3.61
CHAPTER 4 NATIONAL AND END-USER MARKETS
TABLE 4.1
HOSPITALS AND LABORATORIES IN BELGIUM 4.8
TABLE 4.2
HOSPITALS AND LABORATORIES IN FRANCE 4.14
TABLE 4.3
HOSPITALS AND LABORATORIES IN ITALY 4.20
TABLE 4.4
HOSPITALS AND LABORATORIES IN THE NETHERLANDS 4.28
TABLE 4.5
HOSPITALS AND LABORATORIES IN SPAIN 4.37
TABLE 4.6
HOSPITALS AND LABORATORIES IN THE UNITED KINGDOM 4.44
TABLE 4.7
HOSPITALS AND LABORATORIES IN WEST GERMANY 4.54
TABLE 4.8
GENERAL DATA ON THE COUNTRIES SURVEYED IN THIS REPORT 4.59
TABLE 4.9
ANNUAL INCIDENCE OF GENETIC DISEASE IN THE COUNTRIES
SURVEYED IN THIS REPORT 4.62
TABLE 4.10
DEATH RATES FROM CANCER IN WESTERN EUROPE IN 1986 4.64
TABLE 4.11
DEATHS FROM CANCER IN WESTERN EUROPE IN 1986 4.65
CHAPTER 5 MARKET ANALYSES AND FORECASTS
TABLE 5.1
MATERIALS COSTS IN SOUTHERN BLOT DNA DIAGNOSTIC TESTS 5.6
TABLE 5.2
MEDICAL GENETICS MARKET IN WESTERN EUROPE IN 1989 5.18
TABLE 5.3
MARKET FOR DNA DIAGNOSTIC SERVICES IN MONOGENIC
DISORDERS 1989-1995 5.19
TABLE 5.4
MARKET FOR DNA DIAGNOSTIC SERVICES IN CHROMOSOMAL
DISORDERS 1989-1995 5.20
TABLE 5.5
COMMERCIAL COMPANIES CURRENTLY OFFERING DNA
DIAGNOSTIC PRODUCTS AND SERVICES FOR
MEDICAL GENETICS 5.21
TABLE 5.6
COMMERCIAL COMPANIES CURRENTLY OFFERING
DNA PROFILING PRODUCTS AND SERVICES 5.22
TABLE 5.7
MARKET FOR DNA PROFILING SERVICES 1989-1995 5.23
TABLE 5.8
COMMERCIAL COMPANIES CURRENTLY OFFERING
DNA DIAGNOSTIC CANCER-RELATED PRODUCTS 5.24
TABLE 5.9
CERVICAL SCREENING IN WESTERN EUROPE (1989) 5.25
TABLE 5.10
MARKET FOR DNA DIAGNOSTIC PRODUCTS IN CERVICAL
CYTOLOGY 1989-1995 5.26
TABLE 5.11
MARKET FOR CANCER-RELATED DNA DIAGNOSTIC
CHROMOSOMAL ANALYSES 1989-1995 5.27
TABLE 5.12
COMMERCIAL COMPANIES SUPPLYING OR DEVELOPING
DNA TESTS FOR INFECTIOUS DISEASES 5.34
TABLE 5.13
EUROPEAN MICROBIOLOGY MARKET IN 1989 BY COUNTRY AND
END-USER INDUSTRY 5.35
TABLE 5.14
OVERVIEW OF THE EUROPEAN CLINICAL MICROBIOLOGY
MARKET IN 1989 BY COUNTRY AND BY PRINCIPAL TEST 5.36
TABLE 5.15
MARKET FOR AIDS DNA DIAGNOSTIC TESTS 1989-1995 5.37
TABLE 5.16
MARKET FOR DNA DIAGNOSTIC TESTS FOR SEXUALLY-
TRANSMITTED DISEASES 1989-1995 5.38
TABLE 5.17
MARKET FOR DNA DIAGNOSTIC TESTS FOR
ENTERIC PATHOGENS 1989-1995 5.39
TABLE 5.18
MARKET FOR DNA DIAGNOSTIC MYCOBACTERIAL TESTS 1989-1995 5.40
TABLE 5.19
DNA DIAGNOSTIC VIRAL HEPATITIS TESTING MARKET 1989-1995 5.41
TABLE 5.20
MARKET FOR DNA DIAGNOSTIC INSTRUMENTATION 1989-1995 5.42
| |
